These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

703 related articles for article (PubMed ID: 19383615)

  • 1. Risk factors for severe Dysphagia after concurrent chemoradiotherapy for head and neck cancers.
    Koiwai K; Shikama N; Sasaki S; Shinoda A; Kadoya M
    Jpn J Clin Oncol; 2009 Jul; 39(7):413-7. PubMed ID: 19383615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensive chemoradiotherapy as a primary treatment for organ preservation in patients with advanced cancer of the head and neck: efficacy, toxic effects, and limitations.
    Hanna E; Alexiou M; Morgan J; Badley J; Maddox AM; Penagaricano J; Fan CY; Breau R; Suen J
    Arch Otolaryngol Head Neck Surg; 2004 Jul; 130(7):861-7. PubMed ID: 15262764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors associated with long-term dysphagia after definitive radiotherapy for locally advanced head-and-neck cancer.
    Caudell JJ; Schaner PE; Meredith RF; Locher JL; Nabell LM; Carroll WR; Magnuson JS; Spencer SA; Bonner JA
    Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):410-5. PubMed ID: 18635320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma.
    Brizel DM; Murphy BA; Rosenthal DI; Pandya KJ; Glück S; Brizel HE; Meredith RF; Berger D; Chen MG; Mendenhall W
    J Clin Oncol; 2008 May; 26(15):2489-96. PubMed ID: 18487568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Split course hyperfractionated accelerated radio-chemotherapy (SCHARC) for patients with advanced head and neck cancer: influence of protocol deviations and hemoglobin on overall survival, a retrospective analysis.
    Stadler P; Putnik K; Kreimeyer T; Sprague LD; Koelbl O; Schäfer C
    BMC Cancer; 2006 Dec; 6():279. PubMed ID: 17150114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concomitant chemoradiotherapy for advanced head and neck cancer.
    Lin JC; Jan JS; Hsu CY
    Jpn J Clin Oncol; 1994 Apr; 24(2):94-100. PubMed ID: 8158863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can concomitant-boost accelerated radiotherapy be adopted as routine treatment for head-and-neck cancers? A 10-year single-institution experience.
    Allal AS; Taussky D; Mach N; Becker M; Bieri S; Dulguerov P
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1431-6. PubMed ID: 15050320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dosimetric factors associated with long-term dysphagia after definitive radiotherapy for squamous cell carcinoma of the head and neck.
    Caudell JJ; Schaner PE; Desmond RA; Meredith RF; Spencer SA; Bonner JA
    Int J Radiat Oncol Biol Phys; 2010 Feb; 76(2):403-9. PubMed ID: 19467801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck.
    Garden AS; Harris J; Vokes EE; Forastiere AA; Ridge JA; Jones C; Horwitz EM; Glisson BS; Nabell L; Cooper JS; Demas W; Gore E
    J Clin Oncol; 2004 Jul; 22(14):2856-64. PubMed ID: 15254053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of efficacy and toxicity of chemotherapy with cisplatin, 5-fluorouracil, methotrexate and leucovorin (PFML) and radiotherapy in the treatment of locally advanced squamous cell carcinoma of the head and neck.
    Katori H; Tsukuda M; Taguchi T
    Cancer Chemother Pharmacol; 2007 May; 59(6):789-94. PubMed ID: 17053926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dysphagia after chemoradiotherapy for head-and-neck squamous cell carcinoma: dose-effect relationships for the swallowing structures.
    Dirix P; Abbeel S; Vanstraelen B; Hermans R; Nuyts S
    Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):385-92. PubMed ID: 19553033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution.
    Adelstein DJ; Saxton JP; Rybicki LA; Esclamado RM; Wood BG; Strome M; Lavertu P; Lorenz RR; Carroll MA
    J Clin Oncol; 2006 Mar; 24(7):1064-71. PubMed ID: 16505425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. concomitant chemoradiotherapy with mitomycin C and cisplatin in advanced unresectable carcinoma of the head and neck: phase I-II clinical study.
    Strojan P; Karner K; Smid L; Soba E; Fajdiga I; Jancar B; Anicin A; Budihna M; Zakotnik B
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):365-72. PubMed ID: 18394816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiation treatment interruptions greater than one week and low hemoglobin levels (12 g/dL) are predictors of local regional failure after definitive concurrent chemotherapy and intensity-modulated radiation therapy for squamous cell carcinoma of the head and neck.
    McCloskey SA; Jaggernauth W; Rigual NR; Hicks WL; Popat SR; Sullivan M; Mashtare TL; Khan MK; Loree TR; Singh AK
    Am J Clin Oncol; 2009 Dec; 32(6):587-91. PubMed ID: 19581794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the role of prophylactic gastrostomy tube placement prior to definitive chemoradiotherapy for head and neck cancer.
    Chen AM; Li BQ; Lau DH; Farwell DG; Luu Q; Stuart K; Newman K; Purdy JA; Vijayakumar S
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1026-32. PubMed ID: 20231073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parameters that predict local control after definitive radiotherapy for squamous cell carcinoma of the head and neck.
    Mendenhall WM; Morris CG; Amdur RJ; Hinerman RW; Mancuso AA
    Head Neck; 2003 Jul; 25(7):535-42. PubMed ID: 12808656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of concurrent chemoradiotherapy as a palliative treatment in stage IVB esophageal cancer patients with dysphagia.
    Ikeda E; Kojima T; Kaneko K; Minashi K; Onozawa M; Nihei K; Fuse N; Yano T; Yoshino T; Tahara M; Doi T; Ohtsu A
    Jpn J Clin Oncol; 2011 Aug; 41(8):964-72. PubMed ID: 21742654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of the Total Dysphagia Risk Score (TDRS) as a predictive measure for acute swallowing dysfunction induced by chemoradiotherapy for head and neck cancers.
    Koiwai K; Shikama N; Sasaki S; Shinoda A; Kadoya M
    Radiother Oncol; 2010 Oct; 97(1):132-5. PubMed ID: 20817288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics associated with swallowing changes after concurrent chemotherapy and radiotherapy in patients with head and neck cancer.
    Salama JK; Stenson KM; List MA; Mell LK; Maccracken E; Cohen EE; Blair E; Vokes EE; Haraf DJ
    Arch Otolaryngol Head Neck Surg; 2008 Oct; 134(10):1060-5. PubMed ID: 18936351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiogenesis, thymidine phosphorylase, and resistance of squamous cell head and neck cancer to cytotoxic and radiation therapy.
    Koukourakis MI; Giatromanolaki A; Fountzilas G; Sivridis E; Gatter KC; Harris AL
    Clin Cancer Res; 2000 Feb; 6(2):381-9. PubMed ID: 10690514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.